Bentall Operation in a Patient With Severe Hemophilia A and Marfan Syndrome by Use of a Biologic Composite Graft
| dc.contributor.author | Yildirim, F | |
| dc.contributor.author | Ozbakkaloglu, A | |
| dc.contributor.author | Ozturk, T | |
| dc.contributor.author | Tetik, O | |
| dc.date.accessioned | 2025-04-10T10:28:23Z | |
| dc.date.available | 2025-04-10T10:28:23Z | |
| dc.description.abstract | We describe a patient with severe hemophilia A and Marfan syndrome who underwent an elective Bentall operation. Because of the severe hemophilia, anticoagulation could not be given postoperatively; thus, a biologic Valsalva conduit graft was used. During the procedure, factor VIII was given as a bolus dose just before incision, then by continous infusion intra-operatively to maintain the factor VIII activity level between 200% and 300%. Minimal postoperative bleeding occurred. The infusion was continued postoperatively at a lower dose until all chest tubes, pacing wires, and invasive catheters were removed. The patient was discharged on postoperative day 7 without adverse events. (C) 2016 by The Society of Thoracic Surgeons | |
| dc.identifier.e-issn | 1552-6259 | |
| dc.identifier.issn | 0003-4975 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/35234 | |
| dc.language.iso | English | |
| dc.title | Bentall Operation in a Patient With Severe Hemophilia A and Marfan Syndrome by Use of a Biologic Composite Graft | |
| dc.type | Editorial Material |